EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Secosteroid–Isatin Hybrids as Novel Estrogen Receptor α Modulators with Selective Activity Against Hormone-Dependent Breast Cancer

Alexey I. Ilovaisky, Alexander M. Scherbakov, Fedor B. Bogdanov, Valentina M. Merkulova, Elena I. Chernoburova, Andrey S. Dmitrenok, Diana I. Salnikova, Olga E. Andreeva, Danila V. Sorokin, Andrey E. Shchekotikhin, Eugene I. Bozhenko, Mikhail E. Minyaev und 6 weitere

Molecules · 12.11.2026 · 31 (22) · 4071

DOI: 10.3390/molecules31224071 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecules, online erschienen am 12.11.2026. Verfasst von Alexey I. Ilovaisky und 17 weiteren Autor:innen. Die Arbeit nennt 130 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Russian Science Foundation.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Estrogen receptor α (ERα) remains the principal molecular driver of hormone-dependent breast cancer. In this study, we designed, synthesized, and biologically evaluated a new series of secosteroid–isatin hybrids as potential ERα-targeting anticancer agents. The lead compounds, (Z)-3a and (Z)-3b, inhibited MCF-7 cell growth with IC50 values of 6.8 and 6.0 μM, respectively, comparable to cisplatin; they were approximately threefold less potent against epithelial cells than against the target cell model of ERα-positive breast cancer. Mechanistic studies demonstrated that both compounds induced a concentration-dependent depletion of ERα protein, accompanied by downregulation of the ERα-dependent proliferative mediator cyclin D1 and the anti-apoptotic protein Mcl-1, together with accumulation of cleaved PARP, indicating activation of apoptotic cell death. Importantly, an estrogen response element (ERE)-driven luciferase reporter assay demonstrated potent concentration-dependent suppression of 17β-estradiol-induced ERα transcriptional activity, with nearly complete inhibition achieved at higher concentrations, confirming that these compounds function as effective antagonists of ERα-dependent gene transcription. Furthermore, both lead compounds exhibited predominantly synergistic interactions with doxorubicin and heliomycin, suggesting their potential utility in combination therapy. Collectively, these findings identify secosteroid–isatin hybrids as a previously unexplored class of ERα modulators with efficient suppression of estrogen receptor α signaling and induction of apoptosis, which highlights this scaffold as a promising platform for the development of next-generation therapeutics for hormone-dependent breast cancer.

Förderung

  • Russian Science Foundation

Zitieren

APA

Ilovaisky, A. I., Scherbakov, A. M., Bogdanov, F. B., Merkulova, V. M., Chernoburova, E. I., Dmitrenok, A. S., Salnikova, D. I., Andreeva, O. E., Sorokin, D. V., Shchekotikhin, A. E., Bozhenko, E. I., Minyaev, M. E., Pham, Q. L., Nghi, D. H., Quynh, D. T., Yaremenko, I. A., Zavarzin, I. V., & Terent’ev, A. O. (2026). Secosteroid–Isatin Hybrids as Novel Estrogen Receptor α Modulators with Selective Activity Against Hormone-Dependent Breast Cancer. Molecules, 31(22), 4071. https://doi.org/10.3390/molecules31224071

Vancouver

Ilovaisky AI, Scherbakov AM, Bogdanov FB, Merkulova VM, Chernoburova EI, Dmitrenok AS, et al. Secosteroid–Isatin Hybrids as Novel Estrogen Receptor α Modulators with Selective Activity Against Hormone-Dependent Breast Cancer. Molecules. 2026;31(22):4071. doi:10.3390/molecules31224071

BibTeX
@article{Ilovaisky2026,
  author = {Ilovaisky, Alexey I. and Scherbakov, Alexander M. and Bogdanov, Fedor B. and Merkulova, Valentina M. and Chernoburova, Elena I. and Dmitrenok, Andrey S. and Salnikova, Diana I. and Andreeva, Olga E. and Sorokin, Danila V. and Shchekotikhin, Andrey E. and Bozhenko, Eugene I. and Minyaev, Mikhail E. and Pham, Quoc Long and Nghi, Do Huu and Quynh, Dang Thu and Yaremenko, Ivan A. and Zavarzin, Igor V. and Terent’ev, Alexander O.},
  title = {Secosteroid–Isatin Hybrids as Novel Estrogen Receptor α Modulators with Selective Activity Against Hormone-Dependent Breast Cancer},
  journal = {Molecules},
  year = {2026},
  volume = {31},
  number = {22},
  pages = {4071},
  doi = {10.3390/molecules31224071}
}
Kostenlos starten →